200 related articles for article (PubMed ID: 24145996)
1. Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.
Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
Ann Surg Oncol; 2014 Feb; 21(2):677-83. PubMed ID: 24145996
[TBL] [Abstract][Full Text] [Related]
2. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
[TBL] [Abstract][Full Text] [Related]
3. Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.
Koo KC; Cho JS; Bang WJ; Lee SH; Cho SY; Kim SI; Kim SJ; Rha KH; Hong SJ; Chung BH
Cancer Res Treat; 2018 Jan; 50(1):129-137. PubMed ID: 28279064
[TBL] [Abstract][Full Text] [Related]
4. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.
Lee JY; Kang HW; Rha KH; Cho NH; Choi YD; Hong SJ; Cho KS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):849-58. PubMed ID: 26660495
[TBL] [Abstract][Full Text] [Related]
5. Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy.
Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
Yonsei Med J; 2014 Mar; 55(2):316-23. PubMed ID: 24532498
[TBL] [Abstract][Full Text] [Related]
6. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
Moltzahn F; Karnes J; Gontero P; Kneitz B; Tombal B; Bader P; Briganti A; Montorsi F; Van Poppel H; Joniau S; Spahn M
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):31-7. PubMed ID: 25535100
[TBL] [Abstract][Full Text] [Related]
7. Effects of age and comorbidity on survival vary according to risk grouping among patients with prostate cancer treated using radical prostatectomy: A retrospective competing-risk analysis from the K-CaP registry.
Hah YS; Lee KS; Choi IY; Lee JY; Hong JH; Kim CS; Lee HM; Hong SK; Byun SS; Lee SH; Rha KH; Chung BH; Koo KC
Medicine (Baltimore); 2018 Oct; 97(42):e12766. PubMed ID: 30334964
[TBL] [Abstract][Full Text] [Related]
8. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
[TBL] [Abstract][Full Text] [Related]
9. Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.
Boehm K; Dell'Oglio P; Tian Z; Capitanio U; Chun FKH; Tilki D; Haferkamp A; Saad F; Montorsi F; Graefen M; Karakiewicz PI
World J Urol; 2017 Jul; 35(7):1031-1036. PubMed ID: 27796538
[TBL] [Abstract][Full Text] [Related]
10. Cause of Mortality after Radical Prostatectomy and the Impact of Comorbidity in Men with Prostate Cancer: A Multi-institutional Study in Korea.
Pak S; You D; Jeong IG; Lee DE; Kim SH; Joung JY; Lee KH; Hong JH; Kim CS; Ahn H
Cancer Res Treat; 2020 Oct; 52(4):1242-1250. PubMed ID: 32632083
[TBL] [Abstract][Full Text] [Related]
11. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy.
Sivaraman A; Ordaz Jurado G; Cathelineau X; Barret E; Dell'Oglio P; Joniau S; Bianchi M; Briganti A; Spahn M; Bastian P; Chun J; Chlosta P; Gontero P; Graefen M; Jeffrey Karnes R; Marchioro G; Tombal B; Tosco L; van der Poel HH; Sanchez-Salas R
World J Urol; 2016 Oct; 34(10):1367-72. PubMed ID: 26897499
[TBL] [Abstract][Full Text] [Related]
12. A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer.
Lee JY; Cho KS; Kwon JK; Jeh SU; Kang HW; Diaz RR; Ham WS; Koom WS; Keum KC; Choi YD
Ann Surg Oncol; 2014 Nov; 21(12):4026-33. PubMed ID: 24841351
[TBL] [Abstract][Full Text] [Related]
13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
14. Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
Wenzel M; Würnschimmel C; Chierigo F; Tian Z; Shariat SF; Terrone C; Saad F; Tilki D; Graefen M; Mandel P; Kluth LA; Chun FKH; Karakiewicz PI
Prostate; 2021 Aug; 81(11):728-735. PubMed ID: 34010465
[TBL] [Abstract][Full Text] [Related]
15. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Freedland SJ; DeHoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Daskivich TJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):252-260. PubMed ID: 30279582
[TBL] [Abstract][Full Text] [Related]
16. Prediction of mortality after radical prostatectomy by Charlson comorbidity index.
Guzzo TJ; Dluzniewski P; Orosco R; Platz EA; Partin AW; Han M
Urology; 2010 Sep; 76(3):553-7. PubMed ID: 20627284
[TBL] [Abstract][Full Text] [Related]
17. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
Heering M; Berg KD; Brasso K; Iversen P; Røder MA
Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
[TBL] [Abstract][Full Text] [Related]
20. Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.
Preisser F; Mazzone E; Knipper S; Nazzani S; Bandini M; Shariat SF; Tian Z; Saad F; Montorsi F; Zorn KC; Graefen M; Tilki D; Karakiewicz PI
Clin Genitourin Cancer; 2019 Feb; 17(1):e130-e139. PubMed ID: 30366880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
